Skip to main navigation
Skip to search
Skip to main content
Hong Kong Baptist University Home
Help & FAQ
Home
Scholars
Departments / Units
Research Output
Projects / Grants
Prizes / Awards
Activities
Press/Media
Student theses
Datasets
Search by expertise, name or affiliation
View Scopus Profile
Kam Wa CHAN, Prof
Assistant Professor
,
Chinese Medicine - Teaching and Research Division
Associate Director
,
Vincent V.C. Woo Chinese Medicine Clinical Research Institute
https://orcid.org/0000-0002-3175-1574
Email
chriskwc
hkbu.edu
hk
Accepting PhD Students
2011
2025
Research activity per year
Overview
Fingerprint
Network
Projects / Grants
(2)
Research Output
(43)
Prizes / Awards
(1)
Activities
(37)
Similar Scholars
(6)
Fingerprint
Dive into the research topics where Kam Wa CHAN is active. Topic labels come from the works of this scholar. Together they form a unique fingerprint.
Sort by:
Weight
Alphabetically
Keyphrases
Chinese Medicine
75%
Meta-analysis
55%
Systematic Meta-analysis
55%
Chronic Kidney Disease
53%
Diabetic Kidney Disease
50%
Integrative Medicine
42%
COVID-19
40%
Pragmatic Clinical Trial
36%
Diabetes
36%
Estimated Glomerular Filtration Rate
33%
Retrospective Cohort Study
31%
Diabetic Nephropathy
28%
Western Medicine
28%
Randomized Controlled Trial
27%
Catenin
27%
Acute Kidney Injury
27%
Adverse Events
26%
Renal Replacement Therapy
25%
Renal Tubule
23%
Albumin-to-creatinine Ratio
22%
Traditional Chinese Medicine
20%
Type 2 Diabetes Mellitus (T2DM)
19%
Kidney Injury
19%
Chronic Kidney Disease Patients
19%
Chinese Herbal Medicine
19%
Aliskiren
18%
Direct Renin Inhibition
18%
Tubulointerstitial Fibrosis
18%
Hospital Registry
18%
Clinical Trial Design
18%
Parkinson's Disease
18%
IgA Nephropathy (IgAN)
18%
Immunogenicity
18%
Astragalus
18%
Rehmannia
18%
COVID-19 Vaccine
18%
China
18%
Kidney Transplant Recipients
17%
Medicine Services
16%
Confidence Interval
16%
Hong Kong
15%
Type 2 Diabetic Patients
15%
Traditional Medicine
14%
Renal Fibrosis
14%
Chinese Medicine Treatment
14%
Hazard Ratio
14%
Complementary and
12%
Complementary Medicine
12%
Renal Function
12%
Subgroup Analysis
11%
Medicine and Dentistry
Traditional Chinese Medicine
100%
Chronic Kidney Disease
61%
Systematic Review
55%
Randomized Controlled Trial
51%
Medicine
46%
Diabetes
44%
Integrative Medicine
42%
Meta-Analysis
39%
COVID-19
37%
Clinical Trial
37%
Glomerular Filtration Rate
34%
Retrospective Cohort Study
30%
Kidney Function
29%
Diabetic Nephropathy
28%
Acute Kidney Injury
27%
Creatinine
26%
Adverse Event
25%
Fibrosis
20%
Maturity Onset Diabetes of the Young
19%
Nephropathy
19%
Kidney Injury
19%
Chinese Herbal Medicine
19%
Parkinson's Disease
18%
Catenin
18%
Astragalus
18%
Kidney Fibrosis
15%
Diabetes Mellitus
14%
Traditional Medicine
14%
Patient with Type 2 Diabetes
14%
Downregulation
14%
Hazard Ratio
14%
Clinician
14%
Complementary Medicine
12%
Acute Renal Failure
11%
Clinical Trial Design
11%
Adjuvant Therapy
11%
Post-Hoc Analysis
10%
Homeopathy
10%
Lipid Metabolism
10%
Subgroup Analysis
10%
Side Effect
9%
Placebo
9%
Nuclear RNA
9%
Nucleotide Binding Oligomerization Domain Like Receptor
9%
Vorapaxar
9%
Periodontitis
9%
Cell Death
9%
Complement Component C5a
9%
Stroke Rehabilitation
9%
Herbal Agent
9%
Pharmacology, Toxicology and Pharmaceutical Science
Chronic Kidney Failure
75%
Traditional Chinese Medicine
44%
Randomized Controlled Trial
43%
Diabetic Nephropathy
36%
Adverse Event
32%
Cohort Study
27%
Creatinine
25%
Diseases
25%
Clinical Trial
25%
Replacement Therapy
25%
Inflammation
24%
Fibrosis
21%
Non Insulin Dependent Diabetes Mellitus
19%
Aliskiren
18%
Renin Inhibitor
18%
Acute Kidney Failure
18%
Parkinson's Disease
18%
Astragalus
18%
Coronavirinae
18%
Immunoglobulin A Nephropathy
18%
Immunogenicity
18%
COVID-19 Vaccine
18%
Kidney Fibrosis
15%
Diabetes Mellitus
12%
Network Pharmacology
11%
Ureter Obstruction
11%
Renal Diabetes
10%
Placebo
9%
Proteinase Activated Receptor 1
9%
Vorapaxar
9%
Atrasentan
9%
Endothelin Receptor Antagonist
9%
Complement Component C5a
9%
Periodontitis
9%
Chronic Obstructive Lung Disease
9%
Multiinfarct Dementia
9%
Herbal Agent
9%
Cytidine Phosphate
9%
Acetic Acid Derivative
9%
Chemotherapy
9%
Rehmannia
9%
Proline
9%
Catenin
9%
Kidney Injury
9%
Tablet
9%
Side Effect
9%
Breast Cancer
9%
Captopril
9%
Aspartic Acid
9%
SARS Coronavirus
9%